SPHK1 and atherosclerosis: Researchers have speculated that BC294640 targets SphK1 and SphK2 at different concentrations; nonetheless, it is possible that both isoforms were not equally suppressed during treatment, thereby explaining the bidirectional regulatory effect of SphKs on atherosclerosis [176].